Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 18, 2020 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 18, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the closing of its public offering of 2,760,000 of its...
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering
May 13, 2020 23:12 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 13, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 2,400,000 of its...
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
May 13, 2020 17:12 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 13, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of 1,800,000 of...
Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus
May 11, 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Mavrilimumab treatment protocol in patients with severe COVID-19 pneumonia and hyperinflammation showed improved clinical outcomes compared to matched contemporaneous controls, including earlier...
Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
April 28, 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact amid COVID-19 pandemic –– Mavrilimumab treatment protocol in COVID-19 pneumonia and...
Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint
April 22, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8 -- Statistically significant secondary efficacy endpoint of...
Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
March 31, 2020 08:14 ET
|
Kiniksa Pharmaceuticals, Ltd.
- All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation; follow-on controlled study in Italy planned - - Consortium of U.S. academic sites...
Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session
March 30, 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Phase 2 study data show the potential for rilonacept treatment to eliminate or reduce the risk of corticosteroid-associated morbidity in recurrent pericarditis - - Enrollment complete for the...
Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity
February 26, 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 - - Year-end 2019 cash reserves of $233 million - HAMILTON, Bermuda, Feb. 26, 2020 (GLOBE...
Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts
January 13, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Enrollment target achieved for rilonacept Phase 3 trial in recurrent pericarditis; top-line data expected in 2H 2020 -- Enrollment target achieved for mavrilimumab Phase 2 trial in giant cell...